| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| Targets |
Human Endogenous Metabolite
|
|---|---|
| ln Vitro |
Ademetonine, also known as S-Adenosyl-L-methionine tosylate, is involved in three primary metabolic pathways: 1) methylation, which is the body's primary source of methyl groups; 2) transsulfuration, in which Ademetonine forms S-Adenosylhomocysteine (SAH), which is subsequently transformed into homocysteine (Hcy), which can be transformed into cystathionine, and finally into cysteine and sulfate (SO4) to supply additional metabolic intermediates; and 3) Aminopropylation, as Ademetonine is crucial to the synthesis of polyamines, which in turn forms and recycles methionine [2]. Studies conducted in vitro with human articular chondrocytes have demonstrated increases in rabbit proteoglycan production and proliferation rates driven by S-Adenosyl-L-methionine [2].
|
| ln Vivo |
Hepatic S-Adenosyl-L-methionine levels are decreased in mice lacking methionine adenosyltransferase 1a (Mat1a), and they also experience oxidative stress, steatohepatitis, and hepatocellular carcinoma (HCC). On the other hand, persistently elevated liver S-Adenosyl-L-methionine levels may potentially result in damage and HCC. Therefore, to preserve liver health and guard against harm and HCC, appropriate hepatic S-Adenosyl-L-methionine levels are required [3].
|
| References |
[1]. G M Bressa. et al. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7-14.
[2]. Wadie I Najm, et al. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]. BMC Musculoskelet Disord. 2004 Feb 26;5:6. [3]. Shelly C Lu, et al. S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev. 2012 Oct;92(4):1515-42. |
| Molecular Formula |
C22H30N6O8S2
|
|---|---|
| Molecular Weight |
570.64
|
| CAS # |
52248-03-0
|
| Related CAS # |
S-Adenosyl-DL-methionine;17176-17-9;S-Adenosyl-L-methionine disulfate tosylate;97540-22-2;S-Adenosyl-L-methionine iodide;3493-13-8;S-Adenosyl-L-methionine;29908-03-0;S-Adenosyl-L-methionine (1,4-butanedisulfonate);200393-05-1
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C(N)N=CN=C32)O1)O)O.CC1=CC=C(C=C1)S(=O)(=O)O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 150 mg/mL (262.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (175.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7524 mL | 8.7621 mL | 17.5242 mL | |
| 5 mM | 0.3505 mL | 1.7524 mL | 3.5048 mL | |
| 10 mM | 0.1752 mL | 0.8762 mL | 1.7524 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
